New binary solid dispersion of indomethacin with surfactant polymer: From physical characterization to in vitro dissolution enhancement

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1399-1413

  Sivert, Aurélien ^a   Bérard, Véronique ^a   Andrés, Cyrille ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Calorimetry (DSC); Dissolution rate; Physical characterization; Polymeric drug carrier; Preformulation; Solid dispersion; Solid solutions; Solubility; Surfactants

Indexed keywords

INDOMETACIN;

ARTICLE; CRYSTALLIZATION; DISPERSION; DISSOLUTION; DRUG STABILITY; DRUG STORAGE; HEATING; IN VITRO STUDY; MELTING POINT; MISCIBILITY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; WETTABILITY; X RAY DIFFRACTION;

EID: 76649117717     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21935     Document Type: Article

References (51)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv Drug Deliv Rev 46:3-26.
2. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-278.
3. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
4. Curatolo W. 1998. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Sci Technol Today 1:387-393.
5. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. 2007. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 31:249-261.
6. Rasenack N, Müller BW. 2004. Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol 9:1-13.
7. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
8. Hancock BD. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
9. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201-230.
10. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins: 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
11. Loftsson T, Hreinsdóttir D, Másson M. 2005. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 302:18-28.
12. Rong L, editor. 2008. Water-insoluble drug formulation. 2nd edition. Boca Raton-London-New York: CRC Press, Taylor & Francis Group.
13. Chiou WL, Riegelman S. 1971. Pharmaceuticals applications of solid dispersion systems. J Pharm Sci 60:1281-1302.
14. Ford JL. 1986. The current status of solid dispersions. Pharm Acta Helv 61:69-88.
15. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
16. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12:1068-1075.
17. Bikiaris D, Papageorgiou GZ, Stergiou A, Pavlidou E, Karavas E, Kanaze F, Georgarakis M. 2005. Physicochemical studies on solid dispersions of poorly water-soluble drugs Evaluation of capabilities and limitations of thermal analysis techniques. Thermochim Acta 439:58-67.
18. Newman A, Engers D, Bates S, Ivanisevic I, Kelly RC, Zografi G. 2008. Characterization of amorphous API:polymer mixtures using X-ray powder diffraction. J Pharm Sci 97:4840-4856.
19. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
20. Karanth H, Shenoy VS, Murthy RR. 2006. Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report. AAPS Pharm Sci Tech 7:E1-E8.
21. O'Brien M, McCauley J, Cohen E. 1984. Indomethacin. In: Florey K, editor. Analytical profiles of drug substances 13. New York: Academic Press. pp 211-238.
22. Legendre B, Feutelais Y. 2004. Polymorphic and thermodynamic study of indomethacin. J Therm Anal Cal 76:255-264.
23. Hamdi N, Feutelais Y, Yagoubi N, de Girolamo D, Legendre B. 2004. Solvates of indomethacin. J Therm Anal Cal 76:985-1001.
24. De Filippis P, Boscolo M, Gibellini M, Rupena P, Rubessa F, Moneghini M. 1991. The release rate of indomethacin from solid dispersions with Eudragit E. Drug Dev Ind Pharm 17:2017-2028.
25. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, Löbenberg R. 2004. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj® 52, lactose, sorbitol, dextrin, and Eudragit® E100. Drug Dev Ind Pharm 30:303-317.
26. Gong K, Viboonkiat R, Rehman IU, Buckton G, Darr JA. 2005. Formation and characterization of porous indomethacin-PVP coprecipitates prepared using solvent-free supercritical fluid processing. J Pharm Sci 94:2583-2590.
27. Wang X, Novoa de Armas H, Blaton N, Michoel A, Van den Mooter G. 2007. Phase characterization of indomethacin in binary solid dispersions with PVP VA64 or Myrj® 52. Int J Pharm 345:95-100.
28. Ford JL, Rubinstein MH. 1978. Phase equilibria and dissolution rate of indomethacin-polyetylene glycol 6000 solid dispersions. Pharm Acta Helv 53:327-332.
29. Ford JL, Rubinstein MH. 1980. Formulation and ageing of tablets prepared from indomethacinpolyethylene glycol 6000 solid dispersions. Pharm Acta Helv 55:1-7.
30. Yu CD. 2003. Polyoxyethylene stearates. In: Rowe CR, Sheskey PJ, Weller PJ, editors. Handbook of pharmaceutical excipients, 4th edition. London, Chicago: Pharmaceutical Press. pp 484-487.
31. Savolainen M, Heinz A, Strachan C, Gordon KC, Yliruusi J, Rades T, Sandler N. 2007. Screening for differences in the amorphous state of indomethacin using multivariate visualization. Eur J Pharm Sci 30:113-123.
32. Yoshioka M, Hancock BC, Zografi G. 1994. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83:1700-1705.
33. Fukuoka E, Makita M, Yamamura S. 1986. Some physicochemical properties of glassy indomethacin. Chem Pharm Bull 34:4314-4321.
34. Andronis V, Zografi G. 2000. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-Cryst Solids 271:236-248.
35. Schmidt AG, Wartewig S, Picker KM. 2004. Polyethylene oxides: Protection potential against polymorphic transitions of drugs? J Raman Spectrosc 35:360-367.
36. Crowley KJ, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91: 492-507.
37. Bhugra C, Shmeis R, Pikal MJ. 2008. Role of mechanical stress in crystallization and relaxation behavior of amorphous indomethacin. J Pharm Sci 97:4446-4458.
38. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 32:2417-2426.
39. Marsac PJ, Li T, Taylor LS. 2009. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 26:139-151.
40. Bartsch SE, Griesser UJ. 2004. Physicochemical properties of the binary system glibenclamide and polyethyleneglycol 4000. J Therm Anal Cal 77:555-569.
41. Liu C, Zhu SJ, Zhou Y, Wei YP, Pei YY. 2006. Enhancement of dissolution of cyclosporine A using solid dispersions with polyoxyethylene (40) stearate. Pharmazie 61:681-684.
42. Lever T. 2007. Optimizing DSC experiments. In: Craig DQM, Reading M, editors. Thermal analysis of pharmaceuticals. Boca Raton-London-New York: CRC Press, Taylor & Francis Group. pp 23-51.
43. Tao J, Sun Y, Zhang GGZ, Yu L. 2009. Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm Res 26:855-864.
44. Lloyd GR, Craig DQM, Smith A. 1997. An investigation into the melting behavior of binary mixes and solid dispersions of paracetamol and PEG 4000. J Pharm Sci 86:991-996.
45. Fini A, Moyano JR, Ginés JM, Perez-Martinez JI, Rabasco AM. 2005. Diclofenac salts, II. Solid dispersions in PEG6000 and Gelucire 50/13. Eur J Pharm Biopharm 60:99-111.
46. Vasanthavada M, Tong WQ (Tony), Joshi Y, Kislalioglu MS. 2005. Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440-448.
47. Wulff M, Aldén M. 1995. Phase equilibria in drugpolymer-surfactant systems. Thermochim Acta 256:151-165.
48. Wulff M, Aldén M, Craig DQM. 1996. An investigation of the critical surfactant concentration for solid solubility of hydrophobic drug in different polyethylene glycols. Int J Pharm 142:189-198.
49. Andronis V, Yoshioka M, Zografi G. 1997. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci 86:346-351.
50. Otsuka M, Kaneniwa N. 1988. A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem Pharm Bull 36:4026-4032.
51. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidoneco-vinyl-acetate) in relation to indomethacin crystallization. Pharm Res 16:1722-1728.